OSE Pharma, dedicated to severe and orphan lung diseases, has announced the nomination of two new board members with a broad international experience and the recruitment of a CFO from the healthcare industry. These appointments are part of the plan to launch phase III of its targeted lung cancer immunotherapy product.

The targeted immunotherapy (OSE2101) is developed for patients with advanced lung cancer (non-small cell lung cancer) and phase III is in preparation. OSE 2101 is activating the T cytotoxic lymphocytes, enabling them to kill the tumor cells expressing the tumor antigens. This major innovative immune therapy is presenting a new hope for cancer patients.  

Jean-Patrick Demonsang will join OSE Pharma as a board member. Former president of Seventure Partners, he successfully oversaw more than 150 companies mainly involved in information technologies and life sciences. Over the last 25 years, as an entrepreneur, Demonsang founded and managed numerous SMEs’ companies as chairman and CEO.

Professor Gérard Tobelem also will become a board member. He is the winner of the 2006 Diderot Innovation Prize. Tobelem held numerous senior positions at the French Ministry of Research and Higher Education and served as executive chairman of the French national blood transfusion service (Etablissement Français du Sang). He also worked as a consultant for the R&D divisions of multinational pharmaceutical companies for several years. He currently is non-executive chairman of the French company Theradiag. He is former professor of hematology at Paris VII University and the former head of the hematology department at Lariboisière Hospital (Paris).

On the operational side, Alexis Peyroles is joining OSE Pharma as CFO. Peyroles has more than 15 years of international experience in the Pharma industry, working for Sanofi then Guerbet in finance or general management.